tbuckley/cabot-search huggingface dataset:
Cardiotoxicity of 5-fluorouracil in patients with gastrointestinal cancer.
Authors: Lourdes Lopez, Paola Catherine Montenegro
Journal: Journal of Clinical Oncology (2012)

689 Background: 5-fluorouracil (5-FU) is a agent of chemotherapy that has been associated with cardiotoxicity infrequently. The reports shown incidence of clinically apparent 5-FU cardiotoxicity in 1.6% for patients receiving 5-FU alone or in combination with another agents. Methods: We investigated the clinical characteristics of 5-FU cardiotoxicity in patients with gastrointestinal cancer treated in instituto nacional de enfermedades neoplasicas (INEN) Lima - Peru between October 2009 and October 2010. Results: Between October 2009 and October 2010, were evaluated 240 cases with gastrointestinal cancer treated with 5-FU alone or plus combinations with another chemotherapy agent, 8 cases (3.3%) had cardiotoxicity. 37.5 % had history of cardiovascular disease, 3 patients had a history of hypertension and 1 patient diabetes mellitus plus hypertension. 50% (4 patients ) had normal EKG prior to treatment, 25% (2 patients) had no EKG, In 12.5% (1patient) had sinus tachycardia and another patient had ventricular extrasystoles were detected. After chemotherapy infusion 75% (6) had changes in the EKG. In 8 patients was observed as the main symptom chest pain with radiation to left arm or upper back, without elevated cardiac enzymes. 87.5% (7 patients ) had symptoms after 6 pm. And the duration of symptoms was 48 hours in 62.5% (5 patients), 12.5% (1patient ) in 24 hours and 6 hours in 12.5% (1 patient). One patient died of acute heart failure and had history of hypertension and diabetes mellitus and received the combination cisplatin - 5-FU. Conclusions: The eight cases reports confirm the potential cardiotoxicity of 5-FU and argues the need for cardiovascular assessment by a specialist before the start of treatment in addition to cardiac monitoring in patients during treatment, especially in patients with risk factors especially in the first cycle, women and at night. The mechanism of 5-FU cardiotoxicity is not fully elucidated. Coronary spasm is the most accepted hypothesis.
Abstract LB-156: Increased Notch1 expression suppressed the growth but promoted the stemness of gastric cancer cells
Authors: Chia-Chen Chiu, Chien-Ju Lo, Chien-Heng Shen, Chung-Kuang Lu, Jian-Liang Chou, Pei-Yi Chu, Shu-Huei Hsiao, Min-Jen Tseng, Yu-Wei Leu, Chia-Chen Hsu
Journal: Cancer Research (2015)

Abstract To explore if the Notch pathway were abnormally regulated during gastric tumorigenesis, abnormal DLL1 promoter methylation and inversely correlated mRNA expression were detected in cultured cell lines and patient samples. Elevated DLL1 expression was observed in gastric lesion like gastritis or erosion, but decreased DLL1 expression was detected in all four stages of gastric cancers (n = 44). To identify the effector genes and construct the possible Notch signaling network in gastric cancer, Myc-tagged Notch1 was overexpressed in gastric cancer cell line followed by the chromatin-immuno-precipitation sequencing (ChIP-seq) analysis. In ChIP-seq analysis, antibodies against Notch1, Rbpjκ, and Myc were used to identify the Notch1 targets while antibodies against trimethylated histone 3 at lysine 4 (H3K4me3) or lysine 27 (H3K27me3) were used to detect the associated epigenetic states. We found that the Notch1-overexpression suppressed the gastric tumoral growth, and the target loci-associated H3K4me3 (active chromatin) were reduced while the association with H3K27me3 (suppressive chromatin) were increased. Overall, the H3K4me3 and H3K27me3 combined bivalent marks were increased after Notch1-overexpression, and this was correlated with promoted stemness as indicated by the increased Oct4 and CD44 (reported gastric cancer stem cell like marker) expression. EZH2, a Polycomb protein, was found to be associated with Rbpjκ which further links the Notch signaling together with the maintenance of cell stemness. Therefore, Notch signaling might be critical for tumor formation in gastric cancer. (Supported by: NSC-102-2320-B-194-003-MY3 and NSC-102-2314-B-371-003-MY3, MOST Taiwan) Citation Format: Chia-Chen Chiu, Chien-Ju Lo, Chien-Heng Shen, Chung-Kuang Lu, Jian-Liang Chou, Pei-Yi Chu, Shu-Huei Hsiao, Min-Jen Tseng, Yu-Wei Leu, Chia-Chen Hsu. Increased Notch1 expression suppressed the growth but promoted the stemness of gastric cancer cells. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr LB-156. doi:10.1158/1538-7445.AM2015-LB-156
Highly Sensitive Quenching Probe (QProbe) Method Is Useful to Detect c-Kit Mutation and to Predict Relapse of t(8;21)(q22;q22) Acute Myeloid Leukemia.
Authors: Satoshi Wakita, Hiroki Yamaguchi, Yoshio Mitamura, Fumiko Kosaka, Koiti Inokuchi, Kazuo Dan
Journal: Blood (2009)
Successful Rescue of Refractory/Recurrent Myelogenous Leukemia by Allogeneic Hematopoietic Cell Transplantation and Prophylactic Immunotherapy.
Authors: Jing-Bo Wang, Tong Wu, Wan-Ming Da, Chun-Rong Tong, Xing-Yu Cao, Zhi-Yong Gao, Lujia Dong, Yan-Li Zhao, Yu-Ming Yin, Yuan Sun, Yue Lu, Shu-Quan Ji, Dao-Pei Lu
Journal: Blood (2009)
Alanine-scanning mutagenesis of human signal transducer and activator of transcription 1 to estimate loss- or gain-of-function variants
Authors: Reiko Kagawa, Ryoji Fujiki, Miyuki Tsumura, Sonoko Sakata, Shiho Nishimura, Yuval Itan, Xiao-Fei Kong, Zenichiro Kato, Hidenori Ohnishi, Osamu Hirata, Satoshi Saito, Maiko Ikeda, Jamila El Baghdadi, Aziz Bousfiha, Kaori Fujiwara, Matias Oleastro, Judith Yancoski, Laura Perez, Silvia Danielian, Fatima Ailal, Hidetoshi Takada, Toshiro Hara, Anne Puel, Stéphanie Boisson-Dupuis, Jacinta Bustamante, Jean-Laurent Casanova, Osamu Ohara, Satoshi Okada, Masao Kobayashi
Journal: Journal of Allergy and Clinical Immunology (2016)
81. Development of a Second Generation Stable Lentiviral Packaging Cell Line in Support of Clinical Gene Transfer Protocols
Authors: Melissa Bonner, Zhijun Ma, Sheng Zhou, Aixia Ren, Anantharaman Chandrasekaran, John T. Gray, Brian P. Sorrentino, Robert E. Throm
Journal: Molecular Therapy (2015)

Production of lentiviral vectors for clinical gene transfer trials is challenging due to the cost of acquiring GMP-grade plasmids and the labor intensive nature of making vectors via transient transfection. To facilitate clinical grade lentiviral vector production, we developed a packaging cell line, GPRG, which was used to make a fully stable producer, GPRG-EF1α-hgcOPT. This stable producer is presently supporting two clinical trials for the treatment of X-SCID. While initial results in one of these trials have been positive, the output and potency of this line mandates repeated production runs to supply enough vector for larger subjects, producing only enough for 2-3 cases per 6 day run. A second generation packaging cell line, GPRTG, has been developed and tested as a future platform for lentiviral gene transfer trials. This new cell line expresses codon-optimized HIV-1 gagpol, rev and tat. Expression of Rev, Tat and Vesicular Stomatitis Virus G proteins (VSV-G) are regulated by a Tet-Off/On system. We have improved the performance of the GPRTG cell line relative to GPRG by including the expression of HIV-1 Tat while decreasing the expression of Rev and by the independent re-insertion of the Rev, Tat and VSV-G packaging components. We generated a second fully stable producer, GPRTG-EF1α-hgcOPT, expressing the identical insulated SIN vector as in the first generation line. Both cell lines produce high titer vector preparations (>107 tu/ml) and are stable for at least 3 months of continuous passage. Although the vector titers are similar, GPRTG-EF1α-hgcOPT generated vector shows increased transduction efficiency of hCD34+ cells. PCR analysis of bulk CFU-GMs indicates a 2-fold increase in vector positive colonies and 3-5 fold increase in vector copy number with vector from GPRTG-EF1α-hgcOPT as compared to vector generated from GPRG-EF1α-hgcOPT when used at similar MOIs. We hypothesize that the basis for enhanced transduction efficiency of GPRTG derived vector is due to the expression of Tat and reduced expression of Rev each of which may affect vector transduction potency. In support of this hypothesis, our data show that transiently prepared vectors made with Rev only or in the presence of highly abundant Rev transduce hCD34+ cells less efficiently. We are currently employing the second generation cell line, GPRTG, to support future and on-going clinical protocols to treat other rare hematologic disorders including Wiskott-Aldrich Syndrome and Chronic Granulomatous Disease.
Human CD8+/TCR−/CD56dim/− facilitating Cells Enhance Engraftment of HSC In NOD/SCID/IL2rγnull Recipients.
Authors: Yiming Huang, Mary J Elliott, Deborah M Ramsey, Thomas Miller, Larry D Bozulic, Ashley A Ocker, Bradley J King, Suzanne T. Ildstad
Journal: Blood (2010)
Reversal of Complications Following Intensive Combined Chelation in β-Thalassemia Major Patients.
Authors: Kallistheni Farmaki, Ioanna Tzoumari, Christina Pappa, Christos Tompoukis, Aggeliki Papagianni, Nikos Aggelopoulos, Demetrios Mitas, Vasilios Berdoukas
Journal: Blood (2007)
Use of duloxetine for oxaliplatin-induced neuropathic pain in patients with colorectal cancer: An open-label pilot study.
Authors: C. Teng, H. Teng, Y. Yang, C. Yen, T. Lin, J. Lin, W. Chen, C. Tzeng, W. Wang
Journal: Journal of Clinical Oncology (2011)

e19644 Background: This open-label pilot study is aimed to evaluate the efficacy and tolerability of the antidepressant duloxetine, which is effective for diabetic neuropathic pain, in the treatment of chronic oxaliplatin-induced neuropathic pain (OINP). Methods: We enrolled a total of 39 patients with stage III or IV colorectal cancer with chronic OINP. They were treated with duloxetine by increasing the dose from 30 mg/day to 60 mg/day. Patients’ pain intensity was rated at baseline and 12 weeks after duloxetine administration. The severity of neuropathic pain was evaluated using the visual analog scale (VAS) score, and the grade of neuropathy was evaluated with the National Cancer Institute Common Toxicity Criteria for Adverse Events, version 3 (NCI-CTCAE v3.0). Results: Nine patients (23.1%) discontinued duloxetine before the end of treatment because of adverse events. Of the remaining 30 patients, 19 patients (63.3%) had a VAS score improvement. Among them, 9 (47.4%) showed a simultaneous grade improvement, and the other 10 patients (52.6%) had a stable grade according to NCI-CTCAE v3.0. Twenty of the 30 patients (66.7%) who completed 12 weeks of duloxetine treatment received concurrent chemotherapy while taking duloxetine, and none of these patients showed abnormalities in the levels of serum creatinine or alanine transaminase during the period of the combination treatment with duloxetine and chemotherapy. The same conditions were also observed in those who were treated with duloxetine without concurrent chemotherapy. Conclusions: Duloxetine was effective in treating chronic OINP with tolerable toxicity at a daily dose of 60 mg/day.
Role of targeted therapy in ovarian cancer treatment: a systematic review and meta-analysis of randomized trials
Authors: N. Staropoli, D. Ciliberto, S. Chiellino, T. Del Giudice, F. Caglioti, A. Strangio, A. Salvino, P. Tassone, P. Tagliaferri
Journal: Annals of Oncology (2015)
Comparison of outcomes of patients with hepatocellular carcinoma (HCC) over 2 consecutive decades for a VA population.
Authors: F. Zhong, K. Kim, V. Chang, M. L. Gonzalez, C. Quainoo, M. McPherson, B. Crump, J. Einhorn, T. Kalwar, B. Kasimis
Journal: Journal of Clinical Oncology (2011)

e14536 Background: Hepatocellular carcinoma (HCC) incidence is increasing in the United States. We compared the outcome of HCC patients (pts) over two consecutive decades for a VA population. Methods: In an IRB-approved protocol, we reviewed the records of pts with diagnosis (dx) of HCC seen at a VA Medical Center from 1/1/1990 to 12/31/2009. Demographics, Vietnam era (V) status, stage, alpha-fetoprotein (AFP) level at dx, hepatitis B (HBV) and C (HCV), heavy alcohol use (E), tobacco use (T), BMI, diabetes (DM), ferritin (F) level, and treatment modalities were reviewed. Cox survival regression analysis and tests of proportions were performed. Results: All were men. There were 42 pts were from the first decade (d1) (1990 to 1999) and 72 pts from the 2nd decade (d1) (2000 to2009). The median (M) age at dx was 62.25 yo (35-87) for the whole population (W). Comparison of two decades is shown in the table. For the second decade, more variables were analyzed: M BMI of 70 pts was 25.3 (16.9-42.4). 34 pts (47.2%) were Caucasian, 33 pts (45.8%) African American, and 5 pts (7%) others. 25pts (34.7%) has DM, 57 (79%) E use, and 61 (84.7%) T use. Two pts (2.78%) received transplant, 4 (5.56%) resection, 16 (22%) local therapy (L), and 11 pts (15.3%) systemic therapy. In univariate survival analysis, age (p<0.004), stage (p<0.0001), AFP (p<0.0017), F (p<0.002), and V (p<0.0001) were significant predictors of survival. In multivariate survival analyses that included stage, AFP, F, and V for W, stage (p<0.019), AFP (p<0.0008), and F (p<0.035) were significant predictors. Conclusions: The incidence of hepatocellular carcinoma increased at this medical center. Pts were diagnosed at an earlier stage and survival improved in 2nd decade. Stage, AFP, and ferritin levels were independent predictors of survival. First decade Second decade P value No. of pts 42 72 % HCC/total new cancer 0.58% (42/7,187) 1.07% (72/6,726) P <0.0015 Age (yrs) 64.5 (38-82) 60.0 (35-87) NS Median stage 4 3 P <0.0001 Survival (days) 107.0 (0-2557) 182.5 (3-2,214) P <0.0001 AFP ng/ml 238.4 (0.60-2,603,000) 116.4 (1.1-379,567) NS Ferritin (F) ng/dl 113.1 (19-886) 301.5 (15-2,866) NS HBV 1/32 (3.13%) 6/66 (11%) NS HCV 10/17 (37.0%) 49/69 (71%) NS Vietnam era 9/42 (21.43%) 48/72 (66.7%) P <0.0001
BCR-ABL RNA Levels at the Time of a Complete Cytogenetic Response (CCR) Predict the Duration of CCR in Imatinib-Treated Chronic Myeloid Leukemia Patients.
Authors: Richard D. Press, Zac Love, Ashlie A. Tronnes, Gwen Kurilik, Michael J. Mauro, Michael W. Deininger, Brian J. Druker
Journal: Blood (2004)
Multiple Species of Endothelial Microparticles (EMP) Released from Different Membrane Protein Clustering Domains Exhibit Distinctive Phenotypes and Activities.
Authors: Wenche Jy, Joaquin J. Jimenez, Lucia M. Mauro, Carlos Bidot, Lawrence L. Horstman, Miriam Yaniz, Martha Gonzalez, Yeon-Soong Ahn
Journal: Blood (2006)
Abstract 287: Specific delivery of immunostimulatory RNA via nanoparticles blocks growth of primary and disseminated ovarian tumors
Authors: Thomas Primiano, Bey-ih Chang
Journal: Cancer Research (2015)

Abstract One important mechanism of immune evasion is the accumulation of tumor-infiltrating regulatory T cells creating an immunosuppressive microenvironment in situ. Many new therapies target immune checkpoint receptors, CTLA-4 and PD-1, on immunosuppressive T-cells to reverse tumor immune evasion. Small interfering RNAs (siRNAs) are double stranded, sequence-specific inhibitors of gene expression. The paradigm for using siRNA to block cancer is to target mRNA sequences of oncogenes. Several limitations have suppressed the use of siRNA in human cancer therapy, such as off-target effects and lack of tumor-specific delivery. Additionally, certain siRNA sequence motifs activate toll-like receptors that induce the systemic innate immune response, including induction of interferon and interleukin-6 release that is traditionally considered as an undesirable clinical outcome. The hypothesis proposed here is to control the innate immune response by directing it only to tumors and not other organs by delivering an immunostimulatory siRNA (isRNA) directly to tumors. An isRNA designed to silence no human genes was synthesized as an unmodified triphosphate 19-mer double-stranded RNA with a GUGA motif on the 5′ antisense end. This isRNA was delivered into human ovarian tumors grown from SK-OV-3 cells surgically implanted into the ovaries of immunosuppressed mice by an L1CAM-targeted elastin-like polypeptide (ELP-L) nanoparticle. The isRNA/ELP-L nanocomplex was dosed into ten mice by i.p. injection 14 times at 10 mg/kg with respect to the isRNA over 28 days. The isRNA was delivered to the tumors, not to liver, spleen, heart, or lungs. The total tumor mass and number of disseminated nodules both decreased by 50% with respect to vehicle control. Six ovaries harboring tumors were resected from isRNA/ELP-L nanocomplex-dosed mice and each displayed elevated levels of interferon alpha and interleukin 6 mRNA as determined by RT-PCR. Mean AST, ALT and BUN serum biomarkers of liver and kidney function were elevated by 68%, 128% and 14%, respectively, compared to vehicle dosed mice; none of which were outside average normal levels. These results indicate that specifically targeting isRNA to tumors using a targeted nanoparticle may provide an effective therapy for ovarian cancer, either alone or in combination with agents that affect immune check point pathways in tumors. Citation Format: Thomas Primiano, Bey-ih Chang. Specific delivery of immunostimulatory RNA via nanoparticles blocks growth of primary and disseminated ovarian tumors. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 287. doi:10.1158/1538-7445.AM2015-287
Molecular Characterization of Stem Cell Populations and Specific Clone Tracking of Retrovirally-Marked Chemoprotected Stem Cells before and after Dose-Escalating Chemotherapy.
Authors: Brian C. Beard, Pau Mezquita, Laura J. Peterson, Tobias Neff, Ponni Anandakumar, Alixandra A. Knapp, Hans-Peter Kiem
Journal: Blood (2004)
218. Enhanced Antitumor Immunity Induced By HPV16 and 18 E6/E7 DNA Vaccine in Combination with IL-12 as an Immuno-Adjuvant
Authors: Jian Yan, Minjoung Choi, Jaemi S. Chu, Daniel O. Villarreal, Matthrew P. Morrow, Maria Yang, Amir S. Khan, Kate E. Broderick, Niranjan Y. Sardesai, David B. Weiner
Journal: Molecular Therapy (2015)

Human papillomavirus (HPV) infection is associated with 99% of cervical cancers and approximately 20% of head and neck squamous cell carcinomas. HPV E6- and E7-specific T cell immunity has been considered a critical characteristic of an effective therapeutic vaccine designed to control and eliminate established pre-existing HPV infections and associated cancers. The use of molecular adjuvants is considered an important tool to increase the potency of DNA vaccines further. IL-12 has shown to drive cellular immune responses by aiding the priming and expansion of CD8 T cells. We have previously demonstrated that a highly optimized engineered DNA vaccine targeting HPV 16 and 18 E6/E7 (pGX3001 and pGX3002) elicited potent TH1 and cytotoxic cellular immune responses in a Phase I clinical trial. Here, we sought to determine whether the HPV vaccine-induced antitumor immunity could be further enhanced by the addition of IL12 as an adjuvant. We first demonstrated that IL-12 could enhance HPV16 E6 and E7-specific cellular responses measured by ELISpot in mice (average of 1037 vs 504 SFU/106 splenocytes). Then we performed an in vivo tumor therapy study to determine whether IL-12 could enhance the therapeutic efficacy of pGX3001 in TC-1 tumor bearing C57BL/6 mice. The results induced that mice immunized with pGX3001+IL-12 exhibited smaller tumors compared to those in the no adjuvant group. Thirty days post tumor transplantation, 9 out of 10 mice in the pGX3100+IL-12 group showed complete tumor regression, while there were only 4 out of 10 mice in the pGX3001 group that showed complete tumor regression, indicating that the addition of plasmid-based mouse IL-12 enhanced the vaccine-induced antitumor immunity in a murine model. Furthermore, an additional study in a more relevant, non-human primate model was performed to ensure that the vaccine-induced cellular immune responses could also be augmented by using a rhesus macaque IL-12 plasmid. The data indicated that the addition of IL-12 increased the magnitude of vaccine-induced cellular immune responses about two fold post third immunization (average of 2711 SFU vs 1400 SFU/106 PBMCs as measured by ELISpot). The HPV antigen-specific memory responses in the HPV+IL-12 group were increased more than four-fold compared to the responses in the unadjuvanted group (average of 2570 vs 577 SFU/106 PBMCs). Flow cytometric analysis revealed the induction of both HPV-specific CD4 and CD8 T cells that efficiently increased IFN-γ responses. Both adjuvant and unadjuvanted groups showed an increase in effector and central memory CD8 T cells after immunization, while the IL-12 group exhibited stronger effector memory CD8 T cell responses. Taken together, these data support the further development of this HPV DNA vaccine in combination with IL12 as a cancer immunotherapy candidate.
Abstract B76: Targeting Mcl-1 for radiosensitization of pancreatic cancers
Authors: Qiang Zhang, Dongping Wei, Jason Schreiber, Tasneem Kausar, Theodore Lawrence, Yi Sun, Zaneta Nikolovska-Coleska, Meredith A. Morgan
Journal: Cancer Research (2015)

Abstract In order to identify targets whose inhibition may enhance the efficacy of chemoradiation in pancreatic cancer and, thus, improve survival in patients with locally advanced pancreatic cancer, we conducted an siRNA library screen of 8,800 genes. We identified Mcl-1 (myeloid cell leukemia-1), an anti-apoptotic member of the Bcl-2 family, as a target for sensitizing pancreatic cancer cells to gemcitabine-radiation. Thus, we investigated Mcl-1 inhibition by genetic (siRNA) and pharmacological (small molecule) approaches as a radiosensitizing strategy in pancreatic cancer cells. Mcl-1 depletion by siRNA radiosensitized BxPC-3, Panc-1, and MiaPaCa-2 cells with radiation enhancement ratios (RER) of 1.5±0.06, 1.4±0.03, and 1.3±0.01, respectively, and caused Caspase-3 activation and PARP cleavage. We next tested the ability of the recently identified, selective, small molecule inhibitor of Mcl-1, UMI-77 (Abulwerdi F et al., Mol Cancer Ther, 2014), to inhibit the anti-apoptotic functions of Mcl-1 and radiosensitize in pancreatic cancer cells. Consistent with inhibition of Mcl-1 anti-apoptotic function, UMI-77 (1-5uM) caused dissociation of Mcl-1 from the pro-apoptotic protein Bak. Under these same conditions, UMI-77 produced significant radiosensitization in BxPC-3 and Panc-1 cells (RER: 1.5±0.1 and 1.3±0.04, respectively; P&amp;lt;0.05) with minimal radiosensitization of MiaPaCa-2 cells (1.2±0.07). Since Mcl-1 expression levels are highest in BxPC-3 and Panc-1 cells and lowest in MiaPaCa-2 cells, these results suggest that elevated Mcl-1 protein levels may be a biomarker for radiosensitization by Mcl-1 inhibition. In addition, radiosensitization by UMI-77 was associated with Caspase-3 activation, PARP cleavage, and increased sub-G1 DNA content. In contrast, ABT-737, a well-established inhibitor of Bcl-2, Bcl-XL, and Bcl-w, failed to radiosensitize pancreatic cancer cells suggesting the unique importance of Mcl-1 in radiation survival. Taken together, these results validate Mcl-1 as a target for radiosensitization of pancreatic cancer cells and demonstrate the efficacy of small molecules which displace Mcl-1 from Bak/Bax as radiosensitizers in pancreatic cancer. Furthermore, these results support continued investigation of UMI-77 and its analogues in animal models and in combination with gemcitabine-radiation as a strategy for radiation and chemoradiation sensitization of pancreatic cancers. Citation Format: Qiang Zhang, Dongping Wei, Jason Schreiber, Tasneem Kausar, Theodore Lawrence, Yi Sun, Zaneta Nikolovska-Coleska, Meredith A. Morgan. Targeting Mcl-1 for radiosensitization of pancreatic cancers. [abstract]. In: Proceedings of the AACR Special Conference on Pancreatic Cancer: Innovations in Research and Treatment; May 18-21, 2014; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2015;75(13 Suppl):Abstract nr B76.